RILY
On March 31, 2026, BRC Group Holdings (BRCGH) reported its fourth quarter and full year 2025 financial results, showcasing the company's continued success in navigating the complexities of the small and midcap markets. In his prepared remarks during the conference call, Bryant Riley, Co-CEO of BRCGH, highlighted the
GENK
Despite the challenging environment faced by restaurants in Q4 2025, GEN Korean BBQ continues to adapt and evolve. In a recent conference call, Chairman and CEO David Kim highlighted the company's efforts to navigate these difficulties and position itself for future growth. The Q4 period was marked by
ALTI
AlTi, the premier global wealth management platform, has made significant strides in the past three years since its listing. The company's commitment to serving the ultra-high net worth segment of the wealth landscape has yielded impressive results, with a 70% growth in Assets Under Management (AUM) and client
PLAY
The company reported its fourth-quarter and full-year 2025 results, highlighting significant improvements in same-store sales. Excluding the impact of Winter Storm Fern, which occurred over three days in January, Dave & Buster's saw improvement throughout the fourth quarter. CEO Tarun Lal expressed confidence in the company's
BCAX
In a groundbreaking fourth quarter earnings call, Bicara Therapeutics unveiled an array of remarkable achievements that catapulted the clinical-stage biotech company to unprecedented heights. Under the leadership of CEO Claire Mazumdar, the company has been diligently pioneering bifunctional antibodies for targeted tumor modulation. Their innovative approach combines tumor targeting with
PIII
P3 Health Partners, a leading healthcare provider, recently reported its Q4 2025 earnings, showcasing a promising trajectory for the company in the coming year. CEO Aric Coffman led the conference call, highlighting the significant smart growth the company is experiencing and its expectations for 2026. According to Coffman, P3 Health
WS
Good morning, and welcome to Worthington Steel's third quarter fiscal year 2026 earnings call. After a tumultuous few months, marked by the announcement of their proposed acquisition of Kloeckner, the steel giant has once again demonstrated its resilience and commitment to excellence. As President and Chief Executive Officer
CTSO
CytoSorbents, a leading developer of blood purification technologies, has reported strong sales growth and significant regulatory progress in its fourth quarter and full year 2025 performance. According to the company's Q4 2025 conference call transcript, CytoSorbents' Chief Executive Officer, Dr. Phillip Chan, highlighted the key priorities achieved
NOAH
On March 24th, Noah Holdings, a leading wealth management institution catering to high net worth Chinese clients globally, reported its fourth-quarter and full-year results for 2025. The company's strategic direction remains clear amidst market evolution and restructuring, with a focus on serving global Chinese HNW and UHNW clients
BLRX
In a major breakthrough for glioblastoma treatment, BioLineRx has announced significant progress on its highly innovative molecule, GLIX1. The company's Chief Executive Officer, Phil Serlin, highlighted the advancements made during their fourth quarter and full year 2025 financial results conference call. GLIX1 is a first-in-class oral small molecule
BZAI
In a stellar performance, Blaize Holdings, Inc. has announced its fourth quarter 2025 earnings call, highlighting a remarkable year of growth and success. The company's CEO, Dinakar Munagala, took the stage to discuss the impressive results, which exceeded the upper end of revenue guidance by a significant margin.
LENZ
LENZ Therapeutics has made significant strides in its launch of LNZ100, a once-daily eye drop designed to address presbyopia. According to recent Q4 2025 conference call highlights, the company has surpassed expectations and is setting the stage for a blockbuster market opportunity. In his opening remarks, Evert Schimmelpennink, President and